Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 13/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2468870 | 0.95 | MET (0.46) | METMEN1KMT2APDE4APDE4B | |
| SCHEMBL2466030 | 0.91 | MET (0.44) | METMEN1KMT2APDE4APDE4B | |
| SCHEMBL2466972 | 0.89 | MET (0.50) | METMEN1KMT2APDE4APDE4B | |
| SCHEMBL2468835 | 0.89 | MET (0.58) | METMEN1KMT2AHDAC1 | |
| SCHEMBL2496053 | 0.89 | MET (0.44) | METMEN1KMT2APDE4APDE4B | |
| SCHEMBL2496076 | 0.88 | MET (0.47) | METMEN1KMT2APDE4APDE4B | |
| SCHEMBL2467270 | 0.88 | MET (0.53) | METMEN1KMT2APDE4APDE4B | |
| SCHEMBL2467459 | 0.88 | MET (0.53) | METMEN1KMT2APDE4APDE4B | |
| SCHEMBL2469045 | 0.88 | MET (0.44) | METMEN1KMT2APDE4APDE4B | |
| SCHEMBL2492883 | 0.86 | MET (0.49) | METMEN1KMT2APDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1960370-B1 | PYRIDIAZINONE DERIVATIVES FOR TUMOUR TREATMENT | MERCK PATENT GMBH (DE) | 2011-10-05 | — | — | EP | claimed |